Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Inc.

www.us.sandoz.com

Latest From Sandoz Inc.

Stock Watch: Investors Reward Those Who Raise Their Guidance

Oncology diagnoses and therefore revenues are returning as we emerge from the pandemic, but the recovery also brings the challenges of reduced diagnostic and eventually vaccine revenues.

Sales & Earnings Stock Watch

Sandoz Champions Stability As It Returns To Growth In Q2

Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.

Sales & Earnings Strategy

Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Sales & Earnings Trends

Gan & Lee Insulins Data Is Boon For Sandoz

Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.

Biosimilars Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register